Business
LGC Capital's leading Australian medical cannabis LP partner, Little Green Pharma, commences commercial sales to patients, has its products accepted for major clinical trials, commences negotiations to export to Germany and announces plans for a new 500,000 square foot site
LGC Capital's leading Australian medical cannabis LP partner, Little Green Pharma, commenc...
About this update from Elixxer Ltd.
[{"type":"text","content":"\n\n\n\nLGC Capital's leading Australian medical cannabis LP partner, Little Green Pharma, commences commercial sales to patients, has its products accepted for major clinical trials, commences negotiations to export to Germany and announces plans for a new 500,000 square foot site\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nMONTREAL, Oct. 5, 2018\n\n\n\n/NOT FOR DISTRIBUTION IN THE UNITED STATES/\nLittle Green Pharma successfully completes second commercial medical cannabis harvest and commences sales to Australian patients. LGP's products accepted into major statewide clinical trials for advanced cancer. LGP commences negotiations for exports to Germany. LGP negotiating to build a 400,000 square foot facility on a 500,000 square foot site. MONTREAL, Oct. 5, 2018 /CNW Telbec/ - LGC Capital Ltd. (TSXV: LG) (\"LGC\") is pleased to advise that Australian medical cannabis company Little Green Pharma (LGP) in which LGC has a 14.21% interest, has successfully completed harvest of its second commercial medical cannabis crop from its facility south of Perth in Western Australia. \n\n \n \n\n \nThis quarter, LGP successfully achieved another milestone having produced Australia's first locally grown medicinal cannabis product as well as making its first commercial sales to Australian patients. \nLGP has also commenced negotiations with German parties for exporting Australian products. LGP sees potential exports to Germany as being a crucial building block for the business going forward and plans to finalize negotiations within the month, which will be a catalyst for the expansion plan.\nClinical Trials\nLast week, LGP's products were accepted into the NSW state-wide clinical trial for advanced cancer. This is another major tick of approval for LGP products and will enable LGP to directly compare its products' efficacy with a range of other imported products.\nExpansion Plans\nLGP is currently in negotiations to build a purpose-built facility in Perth. Preliminary terms have earmarked a 500,000 square foot block enabling...